Cargando…

Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension

BACKGROUND: There are theoretical concerns that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) could increase the risk of severe Covid-19. OBJECTIVE: To determine if ACEIs and ARBs are associated with an increased risk of Covid-19 hospitalization overall, o...

Descripción completa

Detalles Bibliográficos
Autores principales: Graham, David J., Izurieta, Hector S., Muthuri, Stella G., Zhang, Di, Sandhu, Alexander T., Lu, Yun, Zhao, Yueqin, Feng, Yuhui, Eworuke, Efe, Lyu, Hai, Gandotra, Charu, Smith, Elizabeth R., Avagyan, Armen, Wernecke, Michael, Kelman, Jeffrey A., Forshee, Richard A., MaCurdy, Thomas E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486159/
https://www.ncbi.nlm.nih.gov/pubmed/34599472
http://dx.doi.org/10.1007/s11606-021-07155-z
_version_ 1784577686367109120
author Graham, David J.
Izurieta, Hector S.
Muthuri, Stella G.
Zhang, Di
Sandhu, Alexander T.
Lu, Yun
Zhao, Yueqin
Feng, Yuhui
Eworuke, Efe
Lyu, Hai
Gandotra, Charu
Smith, Elizabeth R.
Avagyan, Armen
Wernecke, Michael
Kelman, Jeffrey A.
Forshee, Richard A.
MaCurdy, Thomas E.
author_facet Graham, David J.
Izurieta, Hector S.
Muthuri, Stella G.
Zhang, Di
Sandhu, Alexander T.
Lu, Yun
Zhao, Yueqin
Feng, Yuhui
Eworuke, Efe
Lyu, Hai
Gandotra, Charu
Smith, Elizabeth R.
Avagyan, Armen
Wernecke, Michael
Kelman, Jeffrey A.
Forshee, Richard A.
MaCurdy, Thomas E.
author_sort Graham, David J.
collection PubMed
description BACKGROUND: There are theoretical concerns that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) could increase the risk of severe Covid-19. OBJECTIVE: To determine if ACEIs and ARBs are associated with an increased risk of Covid-19 hospitalization overall, or hospitalization involving intensive care unit (ICU) admission, invasive mechanical ventilation, or death. DESIGN: Observational case-control study. PARTICIPANTS: Medicare beneficiaries aged ≥ 66 years with hypertension, treated with ACEIs, ARBs, calcium channel blockers (CCBs), or thiazide diuretics. MAIN MEASURES: Adjusted odds ratios (OR) and 95% confidence intervals (CI) for the outcomes of Covid-19 hospitalization, or hospitalization involving ICU admission, invasive mechanical ventilation, or death. RESULTS: A total of 35,300 cases of hospitalized Covid-19 were matched to 228,228 controls on calendar date and neighborhood of residence. The median age of cases was 79 years, 57.4% were female, and the median duration of hospitalization was 8 days (interquartile range 5–12). ACEIs and ARBs were associated with a slight reduction in Covid-19 hospitalization risk compared with treatment with other first-line antihypertensives (OR for ACEIs 0.95, 95% CI 0.92–0.98; OR for ARBs 0.94, 95% CI 0.90–0.97). Similar results were obtained for hospitalizations involving ICU admission, invasive mechanical ventilation, or death. There were no meaningful differences in risk for ACEIs compared with ARBs. In an analysis restricted to monotherapy with a first-line agent, CCBs were associated with a small increased risk of Covid-19 hospitalization compared with ACEIs (OR 1.09, 95% CI 1.04–1.14), ARBs (OR 1.10, 95% CI 1.05–1.15), or thiazide diuretics (OR 1.11, 95% CI 1.03–1.19). CONCLUSIONS: ACEIs and ARBs were not associated with an increased risk of Covid-19 hospitalization or with hospitalization involving ICU admission, invasive mechanical ventilation, or death. The finding of a small increased risk of Covid-19 hospitalization with CCBs was unexpected and could be due to residual confounding. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11606-021-07155-z.
format Online
Article
Text
id pubmed-8486159
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-84861592021-10-04 Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension Graham, David J. Izurieta, Hector S. Muthuri, Stella G. Zhang, Di Sandhu, Alexander T. Lu, Yun Zhao, Yueqin Feng, Yuhui Eworuke, Efe Lyu, Hai Gandotra, Charu Smith, Elizabeth R. Avagyan, Armen Wernecke, Michael Kelman, Jeffrey A. Forshee, Richard A. MaCurdy, Thomas E. J Gen Intern Med Original Research BACKGROUND: There are theoretical concerns that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) could increase the risk of severe Covid-19. OBJECTIVE: To determine if ACEIs and ARBs are associated with an increased risk of Covid-19 hospitalization overall, or hospitalization involving intensive care unit (ICU) admission, invasive mechanical ventilation, or death. DESIGN: Observational case-control study. PARTICIPANTS: Medicare beneficiaries aged ≥ 66 years with hypertension, treated with ACEIs, ARBs, calcium channel blockers (CCBs), or thiazide diuretics. MAIN MEASURES: Adjusted odds ratios (OR) and 95% confidence intervals (CI) for the outcomes of Covid-19 hospitalization, or hospitalization involving ICU admission, invasive mechanical ventilation, or death. RESULTS: A total of 35,300 cases of hospitalized Covid-19 were matched to 228,228 controls on calendar date and neighborhood of residence. The median age of cases was 79 years, 57.4% were female, and the median duration of hospitalization was 8 days (interquartile range 5–12). ACEIs and ARBs were associated with a slight reduction in Covid-19 hospitalization risk compared with treatment with other first-line antihypertensives (OR for ACEIs 0.95, 95% CI 0.92–0.98; OR for ARBs 0.94, 95% CI 0.90–0.97). Similar results were obtained for hospitalizations involving ICU admission, invasive mechanical ventilation, or death. There were no meaningful differences in risk for ACEIs compared with ARBs. In an analysis restricted to monotherapy with a first-line agent, CCBs were associated with a small increased risk of Covid-19 hospitalization compared with ACEIs (OR 1.09, 95% CI 1.04–1.14), ARBs (OR 1.10, 95% CI 1.05–1.15), or thiazide diuretics (OR 1.11, 95% CI 1.03–1.19). CONCLUSIONS: ACEIs and ARBs were not associated with an increased risk of Covid-19 hospitalization or with hospitalization involving ICU admission, invasive mechanical ventilation, or death. The finding of a small increased risk of Covid-19 hospitalization with CCBs was unexpected and could be due to residual confounding. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11606-021-07155-z. Springer International Publishing 2021-10-01 2021-12 /pmc/articles/PMC8486159/ /pubmed/34599472 http://dx.doi.org/10.1007/s11606-021-07155-z Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021
spellingShingle Original Research
Graham, David J.
Izurieta, Hector S.
Muthuri, Stella G.
Zhang, Di
Sandhu, Alexander T.
Lu, Yun
Zhao, Yueqin
Feng, Yuhui
Eworuke, Efe
Lyu, Hai
Gandotra, Charu
Smith, Elizabeth R.
Avagyan, Armen
Wernecke, Michael
Kelman, Jeffrey A.
Forshee, Richard A.
MaCurdy, Thomas E.
Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension
title Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension
title_full Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension
title_fullStr Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension
title_full_unstemmed Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension
title_short Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension
title_sort risk of covid-19-related hospitalization and more severe outcomes in medicare beneficiaries treated with renin-angiotensin-aldosterone system inhibitors for hypertension
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486159/
https://www.ncbi.nlm.nih.gov/pubmed/34599472
http://dx.doi.org/10.1007/s11606-021-07155-z
work_keys_str_mv AT grahamdavidj riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension
AT izurietahectors riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension
AT muthuristellag riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension
AT zhangdi riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension
AT sandhualexandert riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension
AT luyun riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension
AT zhaoyueqin riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension
AT fengyuhui riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension
AT eworukeefe riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension
AT lyuhai riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension
AT gandotracharu riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension
AT smithelizabethr riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension
AT avagyanarmen riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension
AT werneckemichael riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension
AT kelmanjeffreya riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension
AT forsheericharda riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension
AT macurdythomase riskofcovid19relatedhospitalizationandmoresevereoutcomesinmedicarebeneficiariestreatedwithreninangiotensinaldosteronesysteminhibitorsforhypertension